Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Johnson and Johnson
Merck
Colorcon
Mallinckrodt

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Orion Pharma Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for ORION PHARMA, and when can generic versions of ORION PHARMA drugs launch?

ORION PHARMA has two approved drugs.

There are two US patents protecting ORION PHARMA drugs.

There are fifty-five patent family members on ORION PHARMA drugs in forty-one countries.

Summary for Orion Pharma
International Patents:55
US Patents:2
Tradenames:7
Ingredients:2
NDAs:2

Drugs and US Patents for Orion Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orion Pharma STALEVO 100 carbidopa; entacapone; levodopa TABLET;ORAL 021485-002 Jun 11, 2003 AB RX Yes No 6,797,732   See Pricing Y   See Pricing
Orion Pharma STALEVO 200 carbidopa; entacapone; levodopa TABLET;ORAL 021485-004 Aug 2, 2007 RX Yes Yes 6,797,732   See Pricing Y   See Pricing
Orion Pharma STALEVO 75 carbidopa; entacapone; levodopa TABLET;ORAL 021485-005 Aug 29, 2008 RX Yes No 6,797,732   See Pricing Y   See Pricing
Orion Pharma STALEVO 125 carbidopa; entacapone; levodopa TABLET;ORAL 021485-006 Aug 29, 2008 RX Yes No 6,500,867   See Pricing Y   See Pricing
Orion Pharma STALEVO 50 carbidopa; entacapone; levodopa TABLET;ORAL 021485-001 Jun 11, 2003 RX Yes Yes 6,500,867   See Pricing Y   See Pricing
Orion Pharma STALEVO 50 carbidopa; entacapone; levodopa TABLET;ORAL 021485-001 Jun 11, 2003 RX Yes Yes 6,797,732   See Pricing Y   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Orion Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Orion Pharma STALEVO 200 carbidopa; entacapone; levodopa TABLET;ORAL 021485-004 Aug 2, 2007 5,112,861   See Pricing
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999 6,599,530   See Pricing
Orion Pharma STALEVO 125 carbidopa; entacapone; levodopa TABLET;ORAL 021485-006 Aug 29, 2008 5,135,950   See Pricing
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999 4,963,590   See Pricing
Orion Pharma STALEVO 100 carbidopa; entacapone; levodopa TABLET;ORAL 021485-002 Jun 11, 2003 5,135,950   See Pricing
Orion Pharma STALEVO 150 carbidopa; entacapone; levodopa TABLET;ORAL 021485-003 Jun 11, 2003 5,446,194   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ORION PHARMA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 50 mg/200 mg/200 mg ➤ Subscribe 2008-08-28
➤ Subscribe Tablets 18.75 mg/75 mg/200 mg and 31.25 mg/125 mg/200 mg ➤ Subscribe 2009-05-19
➤ Subscribe Tablets 25/100/200 mg and 37.5/150/200 mg ➤ Subscribe 2007-06-29
➤ Subscribe Tablets 25/100/200 mg and 37.5/150/200 mg ➤ Subscribe 2007-06-29
➤ Subscribe Tablets 12.5 mg, 50 mg and 200 mg ➤ Subscribe 2008-08-05
➤ Subscribe Tablets 200 mg ➤ Subscribe 2007-04-11
➤ Subscribe Tablets 18.75 mg/75 mg/200 mg and 31.25 mg/125 mg/200 mg ➤ Subscribe 2009-05-19
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Medtronic
Harvard Business School
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.